Novartis Personalized Cell Therapy Receives FDA Breakthrough Therapy Designation
FDA grants breakthrough therapy designation to Novartis chimeric antigen receptor therapy.
Novartis reported that FDA granted breakthrough therapy status to CTL019, an investigational chimeric antigen receptor (CAR) therapy for the treatment of pediatric and adult patients with relapsed/refractory acute lymphoblastic leukemia (r/r ALL). The breakthrough therapy filing was submitted by the University of Pennsylvania's Perelman School of Medicine (Penn), which has an exclusive global agreement with Novartis to research, develop, and commercialize personalized CAR T-cell therapies for the treatment of cancers. Researchers at Penn noted strong, positive early data in pediatric and adult patients with r/r ALL and hope to build on these findings as they advance the CTL019 clinical program in Phase II trials.
Novartis recently established the Cell and Gene Therapies Unit to focus on advancing cell-based therapies, including the development of CARs. Novartis holds the worldwide rights to CARs developed through the collaboration with Penn for all cancer indications, including the lead program, CTL019.
Source: Novartis
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
